Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06047379 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
A Phase 1 study of Colorectal Cancer and Gastric Cancer, sponsored by Neonc Technologies.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 134
- Enrollment target
- 6
- Study locations
NCT06047379: Recruiting Phase 1 study of Colorectal Cancer and Gastric Cancer, sponsored by Neonc Technologies.
NCT06047379 is a Phase 1 study of Colorectal Cancer and Gastric Cancer that is actively recruiting participants, run by Neonc Technologies. The registered enrollment target is 134 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06047379, a Phase 1 study of Colorectal Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Neonc Technologies.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 134 participants
- Enrollment target
- 6
- Study locations
Study Summary
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b.
Primary Outcome
As determined by incidence and severity of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Regorafenib
- DRUG NEO212 Oral Capsule
Study Locations (6)
California
- Precision NextGen Oncology - Beverly Hills
- OPN Healthcare, Inc - Glendale
- University of Southern California - Los Angeles
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- Baylor, Scott and White Research Institute - Dallas
Washington
- Northwest Medical Specialties - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 1 |
What NCT06047379 shows while recruiting
NCT06047379 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (91% lower).
The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06047379 lists 6 locations in 4 states (California, Tennessee, Texas).
Frequently Asked Questions
What is clinical trial NCT06047379 about?
NCT06047379 is a clinical study titled "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis". This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the ...
What is the current status of trial NCT06047379?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2023-11-01. Estimated completion is 2027-08-31.
What conditions does trial NCT06047379 study?
This clinical trial studies the following conditions: Colorectal Cancer, Gastric Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06047379?
The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG), Regorafenib (DRUG), NEO212 Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT06047379?
This trial is sponsored by Neonc Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06047379 being conducted?
This trial has 6 study locations across California, Tennessee, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06047379's enrollment target sits among peer trials
134 189th of 381 higher than 192 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI